Lingkang Pharmaceutical (603669.SH) subsidiary's product, injectable huperzine A, selected for interprovincial alliance procurement.

Zhitong Finance APP reported that Lingkang Pharmaceutical (603669.SH) announced that its wholly-owned subsidiary, Hainan Lingkang Pharmaceutical Co., Ltd., participated in the bidding for the inter-provincial alliance centralized bulk procurement of 34 types of drugs led by Henan Province. According to the "Notice of Inter-Provincial Alliance Procurement Office for 34 Types of Drugs (No. 8)" issued on August 11, 2026, on the Henan Provincial Medical Centralized Procurement Platform, the subsidiary's product, injection-type huperzine A (brand name: Ruilisu), has been selected for this procurement.